At a time when the imminent rate hike in December has once again made investors cautious about its consequences on the investment world, …
Needham’s healthcare analyst Alan Carr weighted in today on the pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) and San Diego biopharmaceutical company Regulus Therapeutics Inc (NASDAQ:RGLS), after …
Analyst Alan Carr of Needham rates stocks in the biotechnology sector and is one of the top 25 analysts rated on TipRanks. Today, …
J.P.
Following the recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (NASDAQ:GILD) announced that its Phase 3 Study 115 evaluating Zydelig® …
Analysts are weighing in on pharmaceutical giants Gilead Sciences, Inc. (NASDA:GILD), Regeneron Pharmaceuticals Inc (NASDAQ:REGN), and Abbott Laboratories (NYSE:ABT) with mixed ratings.
The options market appears to be underestimating the risk to Gilead Sciences, Inc. (NASDAQ:GILD)’s share price ahead of an event that could intensify …
Gilead Sciences, Inc. (NASDAQ:GILD) announced that the U.
Top-ranked analyst Alan Carr weighed in on two biotech giants this week, Gilead Sciences, Inc. (NASDAQ:GILD) and Intercept Pharmaceuticals Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) announced that it has submitted a New Drug Application (NDA) to the U.
